Jardiance Geriatric (65+) Safety: What Older Adults and Their Clinicians Need to Know

Why Age 65 Is a Meaningful Clinical Threshold for Empagliflozin

Physiologic aging changes every pharmacokinetic variable that matters for empagliflozin. Glomerular filtration rate declines roughly 1 mL/min/1.73 m² per year after age 40, leaving the average 70-year-old with an eGFR 25 to 35 points below their peak adult value even without diagnosed kidney disease [1]. Because empagliflozin's glycemic effect depends entirely on urinary glucose excretion, that age-related filtration loss reduces glucose-lowering efficacy before any labeled contraindication is reached [2].

Body water decreases with age too, roughly dropping from 60% to 50% of total body weight, making older adults substantially more susceptible to the osmotic diuresis empagliflozin produces [3]. Polypharmacy compounds this. Adults over 65 fill an average of 4.5 prescription medications, and combination with thiazides, loop diuretics, ACE inhibitors, or ARBs multiplies volume-depletion risk in ways younger patients rarely face [4].

The cardiovascular and renal benefits that make empagliflozin attractive in high-risk older adults are real and substantial. EMPA-REG OUTCOME (N=7,020, mean age 63.1 years) showed a 38% relative reduction in cardiovascular death (2.5% vs. 3.9%, P<0.001) and a 32% reduction in incident or worsening nephropathy versus placebo over a median 3.1-year follow-up [5]. Those benefits do not disappear after 65. A pre-specified subgroup analysis from the same trial found consistent cardiovascular mortality reduction in patients aged 65 and older, with a hazard ratio of 0.57 (95% CI 0.37 to 0.87) [5]. Benefit persists. Risk profile changes. Managing both simultaneously is the clinical task.

Renal Function: The Primary Dosing Governor in Older Adults

Empagliflozin's FDA-approved labeling ties glycemic use directly to eGFR, and older patients cross these thresholds more often than any other age group [6].

For adults with type 2 diabetes, the 2023 FDA labeling permits empagliflozin for glucose lowering when eGFR is 30 mL/min/1.73 m² or above, but clinical guidance from the American Diabetes Association (ADA) Standards of Care 2024 notes that glycemic efficacy is substantially diminished once eGFR falls below 45 mL/min/1.73 m² [7]. At that point, the glucose-lowering rationale weakens even while the cardiorenal rationale persists down to eGFR 20 in heart failure and CKD indications [6].

The EMPEROR-Reduced trial (N=3,730) extended empagliflozin's heart-failure indication to patients with eGFR as low as 20 mL/min/1.73 m², demonstrating a 25% relative risk reduction in cardiovascular death or heart-failure hospitalization (HR 0.75 to 95% CI 0.65 to 0.86, P<0.001) [8]. Older adults with heart failure who have reduced ejection fraction (HFrEF) may therefore remain on empagliflozin for cardiovascular protection well past the point where glycemic benefit has faded.

Practical renal monitoring recommendation: obtain a baseline eGFR and urine albumin-to-creatinine ratio (UACR) before prescribing, recheck eGFR at 3 months, then every 6 months in stable patients, and within 4 weeks after any acute illness or new nephrotoxic agent [7]. Acute illness, contrast media, and NSAID use can each precipitate a rapid eGFR drop that pushes an older patient below the threshold requiring dose re-evaluation or drug discontinuation.

Volume Depletion, Orthostatic Hypotension, and Fall Risk

Volume depletion is the adverse effect most likely to harm an older adult acutely. Empagliflozin produces roughly 300 to 400 mL of additional daily urine output through osmotic diuresis [9]. In a 75-year-old already taking furosemide 40 mg daily for heart failure, that additive effect can precipitate symptomatic hypotension within the first two weeks of therapy.

The EMPA-REG OUTCOME trial reported volume-depletion events in 3.6% of empagliflozin-treated patients versus 2.5% on placebo [5]. Rates in the geriatric subgroup ran higher, particularly among those on background diuretic therapy [5]. A 2019 pharmacovigilance analysis published in the Journal of the American Geriatrics Society identified that adults 65 and older prescribed SGLT2 inhibitors had a statistically higher odds of acute kidney injury (adjusted OR 1.41 to 95% CI 1.12 to 1.77) compared with younger adults on the same drug class [10].

Orthostatic hypotension secondary to volume depletion translates directly into fall events. Falls are the leading cause of injury death in U.S. adults over 65, according to CDC data, with 36 million falls occurring annually and 32,000 resulting in death each year [11]. Empagliflozin itself has not been shown to independently raise fracture risk in large trials, unlike canagliflozin, which showed a fracture signal in CANVAS [12]. The fall risk with empagliflozin is therefore mediated primarily through hemodynamic mechanisms rather than direct bone effects.

Practical steps to reduce fall risk in older empagliflozin users:

• Check standing blood pressure at initiation and at the first follow-up visit.
• Reduce loop diuretic dose by 25 to 50% preemptively in patients with baseline eGFR <60 who are already at target volume status.
• Educate patients and caregivers that dizziness on standing warrants same-day contact with the prescribing team.
• Use the STEADI (Stopping Elderly Accidents, Deaths, and Injuries) fall-risk screening tool at every annual visit [11].

Diabetic Ketoacidosis: Atypical Presentation in Older Adults

SGLT2 inhibitors can trigger euglycemic diabetic ketoacidosis (DKA), a variant where blood glucose may be only modestly elevated (typically 150 to 250 mg/dL) while ketones and anion gap are critically abnormal [13]. Older adults are particularly vulnerable because the presentation mimics dehydration, nausea from unrelated causes, or delirium, all of which are common geriatric presentations that may delay the diagnostic consideration of DKA.

The FDA issued a Drug Safety Communication in 2015 warning about this risk across the SGLT2 inhibitor class, stating: "FDA has identified 73 cases of diabetic ketoacidosis (DKA) associated with SGLT2 inhibitor use... The blood glucose levels at the time of DKA events in the described cases were lower than expected for DKA" [13].

Triggers in older adults include surgical procedures, prolonged fasting, severe infection, reduced caloric intake during acute illness, and alcohol use. Clinicians should instruct all patients to hold empagliflozin 3 to 4 days before elective surgery and to resume only once normal eating has restarted and the clinical team has confirmed metabolic stability [7].

A practical mnemonic for older patients and caregivers: sick day rules for empagliflozin parallel those for metformin. Stop the drug. Drink clear fluids. Call your provider. Restart only when eating and drinking normally.

Genitourinary Infections: Higher Baseline Incidence After 65

Urinary tract infections (UTIs) and genital mycotic infections are the most frequently reported adverse effects of empagliflozin across age groups. In older women, baseline UTI incidence is already elevated due to estrogen deficiency, altered vaginal microbiome, and incomplete bladder emptying from pelvic floor changes [14].

EMPA-REG OUTCOME reported genital mycotic infection rates of 6.4% (women) and 3.1% (men) in the empagliflozin arm versus 1.8% and 0.4% respectively in the placebo arm [5]. Rates in women over 65 are consistently higher in post-marketing registry data than in the trial population, which skewed toward a mean age of 63 and excluded patients with recurrent UTIs at baseline [5].

For older women with recurrent Candida vulvovaginitis on empagliflozin, options include topical azole prophylaxis, review of hygiene practices, and consideration of dose reduction or switch to an alternative agent if infections recur more than three times per year. Older men should be counseled about balanitis and phimosis risk and instructed to report any genital soreness or discharge promptly [15].

Rare but serious: Fournier's gangrene (necrotizing fasciitis of the perineum) has been reported with SGLT2 inhibitors. The FDA added a boxed warning for this condition in 2018 [16]. Incidence is low (fewer than 60 cases identified by FDA in the first five years of SGLT2 inhibitor use), but age, obesity, and immunosuppression, all common in the geriatric population, are recognized risk factors [16].

Drug-Drug Interactions and Polypharmacy Considerations

Older adults carry a high polypharmacy burden, and several drug combinations with empagliflozin warrant specific attention [4].

Diuretics (thiazide and loop). Additive volume depletion is the main concern. A patient on hydrochlorothiazide 25 mg and furosemide 40 mg who starts empagliflozin 10 mg may develop symptomatic orthostatic hypotension within days. Consider reducing or stopping one diuretic before initiation [9].

Insulin and sulfonylureas. Empagliflozin does not cause hypoglycemia on its own, but combining it with insulin or a sulfonylurea such as glipizide creates additive hypoglycemia risk. The ADA 2024 Standards of Care recommend reducing the insulin dose by 10 to 20% when adding an SGLT2 inhibitor to avoid hypoglycemia [7].

NSAIDs. Non-steroidal anti-inflammatory drugs reduce renal perfusion by inhibiting prostaglandin synthesis. Combined with empagliflozin's osmotic diuresis, this creates a compounding risk of acute kidney injury. Older adults are the demographic most likely to use NSAIDs for osteoarthritis. A 2022 cohort study in BMJ found that concurrent NSAID and SGLT2 inhibitor use was associated with a 1.84-fold higher rate of AKI hospitalization versus SGLT2 inhibitor use alone (95% CI 1.61 to 2.10) [17].

ACE inhibitors and ARBs. These agents already reduce intraglomerular pressure; empagliflozin adds further pressure reduction via tubuloglomerular feedback inhibition. The combination is often intentional and beneficial for CKD progression, but requires careful eGFR monitoring at initiation [7].

Digoxin. Empagliflozin can raise digoxin plasma concentrations modestly (by approximately 6% in pharmacokinetic studies) through reduced renal clearance of digoxin secondary to hemodynamic effects [6]. In older patients where digoxin is already dosed narrowly, this interaction justifies a digoxin level check within 2 to 4 weeks of empagliflozin initiation [6].

Efficacy in Older Adults: Do the Cardiorenal Benefits Hold?

The benefits do hold, and this is an often under-recognized clinical point that changes prescribing decisions in the geriatric population.

EMPA-REG OUTCOME's subgroup analysis for patients 65 and older showed that cardiovascular death was reduced by 43% (HR 0.57) compared with a 30% reduction in the under-65 group, suggesting if anything a stronger absolute benefit in older patients given their higher baseline event rate [5]. The number needed to treat (NNT) for cardiovascular death prevention over 3.1 years was approximately 39 in patients 65 and older versus 58 in the younger cohort, based on published event rates [5].

For kidney protection, the EMPA-KIDNEY trial (N=6,609, mean age 63.7 years, published NEJM 2023) demonstrated that empagliflozin reduced the risk of kidney-disease progression or cardiovascular death by 28% (HR 0.72 to 95% CI 0.64 to 0.82, P<0.001) in adults with CKD, including those with eGFR as low as 20 mL/min/1.73 m² [18]. 37% of enrolled patients had eGFR between 20 and 44, a range where many older adults sit.

The EMPEROR-Preserved trial (N=5,988, mean age 71.9 years) showed empagliflozin reduced heart-failure hospitalization by 29% in patients with HFpEF (HR 0.71 to 95% CI 0.60 to 0.83, P<0.001), a condition disproportionately affecting older women [19]. This trial is particularly relevant for geriatric prescribing because its population was older and more comorbid than any prior SGLT2 inhibitor trial [19].

Deprescribing Empagliflozin in Older Adults: A Structured Approach

Deprescribing is not failure. For older adults with advancing frailty, severely reduced eGFR, or limited life expectancy, stopping empagliflozin is often the right clinical decision, and doing it systematically reduces harm.

The following criteria, drawn from ADA 2024 guidance, the 2023 Canadian Deprescribing Network recommendations, and geriatric pharmacology literature, should prompt a deprescribing review [7, 20]:

1. eGFR below 20 mL/min/1.73 m² for patients using empagliflozin solely for glycemic control. Cardiorenal indications may extend use to lower eGFR thresholds.
2. Frailty score of "moderate" or higher on validated tools such as the Clinical Frailty Scale (CFS score 5 or above), where the osmotic diuresis and volume depletion risks outweigh incremental cardiorenal benefit.
3. Life expectancy below 1 year, where preventing long-term cardiovascular events ceases to be a meaningful goal relative to avoiding adverse effects.
4. Recurrent euglycemic DKA or volume-depletion hospitalizations, where the benefit-risk ratio has demonstrably inverted.
5. Active genitourinary infection that has not resolved after two treatment courses, particularly in older women with recurrent Candida or ascending UTI.

When stopping empagliflozin, glucose rebound is minimal in older adults because glycemic efficacy was already reduced at lower eGFR values. Blood pressure may rise slightly (empagliflozin produces a 3 to 5 mmHg reduction in systolic BP), warranting a blood pressure check at 4 weeks post-discontinuation [21]. Weight may increase by 1 to 2 kg due to fluid retention reversal [9].

Initiation Checklist for Clinicians Prescribing to Patients Over 65

Before writing the first prescription for an older adult, the following should be confirmed:

• eGFR and UACR obtained within the past 3 months [7].
• Baseline sitting and standing blood pressure documented [11].
• Current diuretic regimen reviewed; dose reduction planned if eGFR <60 [9].
• Insulin or sulfonylurea doses adjusted downward by 10 to 20% if applicable [7].
• Patient and caregiver counseled on sick-day rules: hold empagliflozin during illness, fasting, or surgery [13].
• STEADI fall-risk assessment documented [11].
• Genital hygiene counseling provided, particularly for women [15].
• Digoxin level ordered at 2 to 4 weeks post-start if patient is on digoxin [6].
• Follow-up eGFR planned for 3 months post-initiation [7].
• Annual review scheduled to reassess benefit-risk balance in the context of changing frailty and renal function [20].

Special Populations Within the Geriatric Group

Adults over 80. Patients in their eighties were underrepresented in every major empagliflozin trial. EMPA-REG OUTCOME enrolled only 7.6% of patients aged 75 or older [5]. Extrapolating cardiovascular benefit to octogenarians requires caution. The osmotic diuresis may be less tolerated, and the absolute cardiovascular benefit may be reduced if competing mortality from frailty-related causes is high. A shared decision-making conversation is mandatory.

Older adults with type 1 diabetes. Empagliflozin is not FDA-approved for type 1 diabetes, and DKA risk is substantially higher in this population [6]. Off-label use in older adults with T1D carries a particularly unfavorable risk-benefit profile and should be avoided.

Older adults with recurrent urinary tract infections. Chronic catheterization, neurogenic bladder from spinal stenosis or prior stroke, and post-void residual urine all amplify UTI risk. A baseline urine culture before initiation, plus a plan for regular surveillance cultures every 6 months, is reasonable in this subgroup [14].

Older adults with osteoporosis. Empagliflozin has not shown an independent fracture signal in the way canagliflozin did in CANVAS, but orthostatic hypotension-related falls remain a concern [12]. Ensure bone mineral density screening is current per USPSTF guidelines (recommended for women 65 and older) and that pharmacologic osteoporosis treatment is optimized before adding any agent that could increase fall frequency [22].